Article Text

This article has a correction. Please see:

PDF
Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study
  1. L Sailler1,
  2. C Pereira1,
  3. A Bagheri1,
  4. M Lapeyre-Mestre1,
  5. J L Montastruc1,
  6. P Arlet2,
  7. E Arlet-Suau2,
  8. E Uro-Coste3,
  9. H Roussel4,
  10. D Adoue5,
  11. B Fournie6,
  12. L Zabraniecki6,
  13. M Laroche7,
  14. P Cintas8
  1. 1
    University of Tolouse, Toulouse, France
  2. 2
    Internal Medicine Department, Salles Le Tallec-Tapie, Pavillon Dieulafoy, CHU Purpan, Toulouse, France
  3. 3
    Pathology Department, CHU Rangueil, Toulouse, France
  4. 4
    Direction Régionale du Service Médical, CNAMTS, Toulouse, France
  5. 5
    Internal Medicine Department, Pavillon des Médecines, CHU Purpan, Toulouse, France
  6. 6
    Rheumatology Department, CHU Purpan, Toulouse, France
  7. 7
    Rheumatology Department, CHU Rangueil, Toulouse, France
  8. 8
    Neurology Department, CHU Rangueil, Toulouse, France
  1. Dr L Sailler, Unit of Pharmacoepidemiology, EA 3696, Clinical Pharmacology Department, Paul Sabatier University, 37 Allées Jules Guesdes, 31000 Toulouse, France; sailler.l{at}chu-toulouse.fr

Abstract

Objective: Case reports have suggested that lipid-lowering drugs (LLDs), especially statins, could induce or reveal chronic muscle diseases. We conducted a study to evaluate the association between chronic muscle diseases and prior exposure to LLDs.

Method: This was a retrospective study of chronic primary muscle disease cases newly diagnosed at the Toulouse University Hospitals between January 2003 and December 2004 among patients living in the Midi-Pyrénées area, France. All patients remained symptomatic for more than 1 year after drug withdrawal, or required drugs for inflammatory myopathy. Data on the patient’s exposure to LLDs and to other drugs were compared with that of matched controls (5/1) selected through the Midi-Pyrénées Health Insurance System database.

Results: A total of 37 patients were included in the study. Of those, 21 (56.8%) suffered from dermatomyositis (DM) or polymyositis (PM), 12 (32.4%) from genetic myopathy, and 4 (10.8%) from an unclassified disease. The prevalence of exposure to statins was 40.5% in patients and 20% in controls (odds ratio (OR) 2.73, 95% confidence interval (CI) 1.21–6.14; p<0.01). There was a significant positive interaction between statins and proton pump inhibitors exposure (weighted OR 3.3, 95% CI 1.37–7.54; p = 0.02). Statin exposure rate was 47.6% among patients with DM/PM (OR 3.86, 95% CI 1.30–11.57; p<0.01). There was no difference between patients and controls for exposure to fibrates.

Conclusion: Patients who developed chronic muscle diseases after the age of 50, including DM/PM, had a higher than expected frequency of prior exposure to statins. Further studies are needed to confirm this association and the role of proton pump inhibitors.

Statistics from Altmetric.com

Footnotes

  • Competing interests: None.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Correction
    BMJ Publishing Group Ltd and European League Against Rheumatism